<DOC>
	<DOCNO>NCT00455910</DOCNO>
	<brief_summary>The GFM previously conduct dose-escalating phase II trial thalidomide MDS minimum dose 200mg/d maximum dose 800mg/d . Responses evaluate accord IWG criterion week 16 thalidomide continue week 56 responder . 82 % patient receive least 8 week treatment evaluable . 59 % hematological improvement , mainly erythroid lineage ( Increase Hemoglobin ) . Most response observe low dos 4 8 week . The objective trial ( Thal-SMD-20 ) evaluate efficacy tolerance low dos thalidomide low risk MDS patient transfusion-dependant anemia .</brief_summary>
	<brief_title>Thalidomide Low Dose Treatment Patient With Myelodysplastic Syndromes - THAL-SMD-200</brief_title>
	<detailed_description>Thalidomide : First part trial : 82 patient 200mg/day give bedtime x 12 week , decrease 100mg/day grade 1 2 side . Stopped temporally 1 week grade 3 4 side effect . Then reintroduce dose . If side effect , definitively stop . Responses evaluate 12 week accord IWG criterion erythroid lineage At week 12 : - If Hematological improvement ( HI ) : increase 300mg/day 8 week eventually 400mg/day 8 week , HI . - If Hematological improvement ( HI ) : continue dose . Second part trial : 30 patient treat 50mg/day x 12 week . Responses evaluate 12 week accord IWG criterion erythroid lineage At week 12 : - If Hematological improvement ( HI ) : increase 100mg/day 8 week eventually 200mg/day 8 week , HI . - If Hematological improvement ( HI ) : continue dose .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients â‰¥18 year , IPSS Low Int1 MDS Transfusion dependant anemia 2 pack red blood cell ( PRBC ) /month ECOG index = 0 , 1 , 2 No peripheral neurological disease MDS patient IPSS Int2 High Patients le 2 packed red blood cell ( PRBC ) /month Patients previous history venous thrombosis Patient treat EPO +/ GCSF 2 month inclusion protocol Patient receive intensive chemotherapy 3 month inclusion protocol Patient receive Thalidomide previous protocol Patient presenting iron , B12 vitamin folic acid uncorrected deficiency Patient peripheral neurological disease Patient able subject regular clinical biological followup Pregnant patient patient period lactation Patient refuse take contraceptive treatment study Patient receive drug able interfere mechanism action Thalidomide Patient refuse sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Low risk myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Bone marrow disease</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Cytopenias</keyword>
	<keyword>Anemia</keyword>
</DOC>